A talented CEO and board member, Deirdre Gillespie specializes in such business areas as general management, clinical development, and corporate finance. Dr. Deirdre Gillespie has raised $200 million in equity financing, maintained high corporate governance standards, and overseen SEC reporting and filings.
Through the United States Securities and Exchange Commission (SEC), investors get a clear view of the history and progress of a company. There are several different forms associated with SEC reporting and filings, starting with registration statements, which are filed by all foreign and domestic companies unless they qualify for an exemption. Registration statements consist of the prospectus, a legal document that details how a business operates and provides insight into any investment risk, and additional information, which includes such things as recent sales of unregistered securities. For companies that are private and looking into becoming public, S-1 and S-2 forms, detailing past revenue and current stock owners, are required.
10-K reports and 10-Q reports are also important SEC filings. The 10-K is filed every year within 90 days of the fiscal year’s end, and includes a business summary and financial statements to allow comprehensive analysis of the company in question. Meanwhile, the 10-Q, submitted within 45 days of the end of each of the first three quarters of the fiscal year, includes information about a company’s direction and new developments. For any information not covered in the 10-K and 10-Q, companies must file an 8-K, an unscheduled document that further details companies’ information and may include such materials as press releases.
The chief executive officer of Invigor Consulting, Dr. Deirdre Gillespie has overseen the dissolution of numerous public companies. Throughout her career, Dr. Deirdre Gillespie has negotiated settlements with 100 percent of her clients’ creditors (more than 250) for less money than they were owed, which mitigated liability and kept the client from filing for bankruptcy.
Dissolving a company is an important and often difficult decision made by its owners. However, it can provide some benefits, such as halting the growth of debt. Nevertheless, shutting down a company requires the proprietors to take several steps in sequence. Before beginning the process, it is important to check the laws of the state of the company’s incorporation or of its principal place of business for any specific requirements that must be met.
Initially, the owners of a company must vote to shut down the business. Corporations generally detail how many votes are needed to close itself down in its bylaws or other documents, but states also have regulations for entities that fail to set their own policies. Subsequently, the company must file the dissolution paperwork with the state; these documents can usually be found on the secretary of state’s website. Any permits, licenses, or out-of-state registrations must also be canceled.
After dissolution begins, the corporation must tell other parties, including its employees, its customers, and utility providers. The business must also inform its creditors about this change of circumstance because it puts them on notice that the company can no longer incur debt. Without this knowledge, creditors may continue providing supplies or money and can sue for a greater repayment amount.
Dr. Deirdre Gillespie began working in pharmaceutical clinical research in the mid-1980s. In the early 1990s, she started focusing on pharmaceutical business development. Since then, Deirdre Gillespie, M.D., has led several biotechnology and pharmaceutical businesses, among them La Jolla Pharmaceutical Company, where she served as CEO for six years. Dr. Gillespie presently serves as CEO of Invigor Consulting in San Diego, through which she offers operational and leadership advice and services to biopharma businesses.
The global biopharma industry continues to experience a boom in mergers and acquisitions (M&A) in 2014 after the record-breaking activity of the year before. Earlier this year, PricewaterhouseCoopers reported that the pharma industry experienced a $45 billion increase in the value of 2013 M&A deals compared with the previous year. That increase marks a more than 45 percent growth in deal values over 2012, which by all accounts proved a poor performance year for biopharma companies.
In 2014, the biopharma M&A activity shows no sign of slowdown. During the second quarter, news outlets reported that industry deal values reached $93 billion, their highest since 2009. Earlier in the year, Pfizer walked away from a $118 billion offer to purchase AstraZeneca after months of negotiations between the two companies fell through. Had the deal gone through, the merger would have been the industry’s largest. And, as of June 2014, Valeant Pharmaceuticals continues to woo Botox maker Allergan in an offer valued at more than $50 billion.